20' Case-based lecture : Navel Daver (Houston)
Immune check-point inhibitors in acute leukaemia
Brief oral communication
5' Phase 1b multicenter, open-label study of the anti–TIM-3 Andrew Wei (Melbourne)
antibody MBG453 in combination with decitabine in patients
with acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS)
30' Panel discussion
50' DEBATE – T-ALL: where are we going now?
Chair: Nicolas Boissel (Paris)
15' Standard and new options for T-ALL David Teachey (Philadelphia)
15' Targeting T cell malignancies with CRISPR/Cas9 Gene John DiPersio (Saint-Louis)
Edited Universal CART
20' Discussion
www.esh.org - info@esh.org 5
60' SATELLITE SYMPOSIUM:
T-cell engaging immuno-oncology therapy in ALL: from clinical trials to real-world evidence
Speakers: Nicolas Boissel (Paris), Christina Peters (Vienna)
This symposium is organised and funded by Amgen
60' SATELLITE SYMPOSIUM:
AML treatment: Where are we heading?
Chair : Andrew Wei (Melbourne)
Speakers: Konstanze Döhner (Ulm), Gail Roboz (New York)
This symposium is organized and funded by Celgene. A Bristol-Myers Squibb company
60' SATELLITE SYMPOSIUM:
AML: Bringing precision medicine and MRD into clinical strategies
Chair : Jorge Sierra (Barcelona)
Speakers: Lionel Adès (Paris), Lars Bullinger (Berlin), Jorge Sierra (Barcelona)
This symposium is organised and funded by Novartis
60' SATELLITE SYMPOSIUM:
Clinical perspectives in AML: Diagnosis, monitoring and treatment
Chair : Jorge Sierra (Barcelona)
Speakers: Jacqueline Cloos (Amsterdam), Pau Montesinos (Valencia),
Jorge Sierra (Barcelona), Andrew Wei (Melbourne)
This symposium is organised and funded by Astellas
SCIENTIFIC
PROGRAMME
RARE SUBSETS OF
ACUTE LEUKAEMIA
TRACKING LEUKAEMIC
STEM CELLS (LSCs)
ROUTINE DIAGNOSIS
GENE EXPRESSION
AND MUTATIONAL
PROFILING
DEBATE 1 – ALL
PATIENTS WITH
INTERMEDIATE-RISK
AML MUST BE
TRANSPLANTED
INTERACTIVE
CASES 1 – MUTATION-BASED
THERAPY
OFF-LABEL
ROUNDTABLE –
SHOULD WE REALLY
USE NEW TARGETED
INHIBITORS AS SINGLE
AGENTS ?
ADDITION OF A 3RD
AGENT TO FRONTLINE
7+3
ROUNDTABLE –
CURATIVE OPTIONS
FOR OLDER AML
INTERACTIVE CASES 2
DEBATE 2 - BEST
TREATMENT FOR
NPM1-MUTATED AML IN
THE NEXT FUTURE ?
ALLOGENEIC
HAEMATOPOIETIC
STEM CELL
TRANSPLANTATION
(HSCT)
IMMUNOTHERAPY FOR
ACUTE LEUKAEMIA
DEBATE 3 - T-ALL:
WHERE ARE WE GOING
NOW?
SELECTED ABSTRACTS
AND CLINICAL
CASES FOR AN ORAL
PRESENTATION
SELECTED ABSTRACTS
FOR A POSTER
PRESENTATION
DISCLOSURES